![Mc Callion Orla](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mc Callion Orla
No open positions remaining
Profile
Mc Callion Orla is currently the Head of Regulatory Affairs & QA at Ultimovacs ASA. Previously, Dr. Orla worked as the Director of Regulatory Affairs at OxThera AB from 2012 to 2021.
Dr. Orla holds a doctorate degree from Queen's University.
Former positions of Mc Callion Orla
| Companies | Position | End |
|---|---|---|
OxThera AB
 OxThera AB Medical/Nursing ServicesHealth Services Develops novel treatments for hyperoxaluria leading to kidney damage and potential organ failure | General Counsel | 2021-09-30 |
Ultimovacs ASA
 Ultimovacs ASA Pharmaceuticals: MajorHealth Technology Develops novel peptide based therapeutic cancer vaccine | General Counsel | - |
Training of Mc Callion Orla
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
10
1st degree connections
3
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Queen's University
 Queen's University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OxThera AB
OxThera AB Medical/Nursing ServicesHealth Services Develops novel treatments for hyperoxaluria leading to kidney damage and potential organ failure | Health Services |
Ultimovacs ASA
Ultimovacs ASA Pharmaceuticals: MajorHealth Technology Develops novel peptide based therapeutic cancer vaccine | Health Technology |
- Stock Market
- Insiders
- Mc Callion Orla
